Cytokinetics Statistics
Share Statistics
Cytokinetics has 119.43M
shares outstanding. The number of shares has increased by 3.27%
in one year.
| Shares Outstanding | 119.43M |
| Shares Change (YoY) | 3.27% |
| Shares Change (QoQ) | 0.34% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,503 |
| FTD / Avg. Volume | 0.07% |
Short Selling Information
The latest short interest is 14.48M, so 12.12% of the outstanding
shares have been sold short.
| Short Interest | 14.48M |
| Short % of Shares Out | 12.12% |
| Short % of Float | 15.82% |
| Short Ratio (days to cover) | 9.62 |
Valuation Ratios
The PE ratio is -8.94 and the forward
PE ratio is -6.8.
Cytokinetics's PEG ratio is
2.56.
| PE Ratio | -8.94 |
| Forward PE | -6.8 |
| PS Ratio | 285.13 |
| Forward PS | 2.4 |
| PB Ratio | -38.91 |
| P/FCF Ratio | -13.18 |
| PEG Ratio | 2.56 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Cytokinetics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.17,
with a Debt / Equity ratio of -5.83.
| Current Ratio | 6.17 |
| Quick Ratio | 6.17 |
| Debt / Equity | -5.83 |
| Debt / EBITDA | -1.6 |
| Debt / FCF | -1.97 |
| Interest Coverage | -6.2 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $37,096.39 |
| Profits Per Employee | $-1,183,787.15 |
| Employee Count | 498 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -48.87% in the
last 52 weeks. The beta is 0.81, so Cytokinetics's
price volatility has been higher than the market average.
| Beta | 0.81 |
| 52-Week Price Change | -48.87% |
| 50-Day Moving Average | 40.6 |
| 200-Day Moving Average | 49.09 |
| Relative Strength Index (RSI) | 29.84 |
| Average Volume (20 Days) | 2,153,055 |
Income Statement
In the last 12 months, Cytokinetics had revenue of 18.47M
and earned -589.53M
in profits. Earnings per share was -5.26.
| Revenue | 18.47M |
| Gross Profit | 8.94M |
| Operating Income | -536.25M |
| Net Income | -589.53M |
| EBITDA | -493.48M |
| EBIT | -503.01M |
| Earnings Per Share (EPS) | -5.26 |
Full Income StatementBalance Sheet
The company has 94.86M in cash and 788.68M in
debt, giving a net cash position of -693.82M.
| Cash & Cash Equivalents | 94.86M |
| Total Debt | 788.68M |
| Net Cash | -693.82M |
| Retained Earnings | -2.7B |
| Total Assets | 1.4B |
| Working Capital | 928.27M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -395.89M
and capital expenditures -3.91M, giving a free cash flow of -399.8M.
| Operating Cash Flow | -395.89M |
| Capital Expenditures | -3.91M |
| Free Cash Flow | -399.8M |
| FCF Per Share | -3.57 |
Full Cash Flow StatementMargins
Gross margin is 48.41%, with operating and profit margins of -2902.72% and -3191.11%.
| Gross Margin | 48.41% |
| Operating Margin | -2902.72% |
| Pretax Margin | -3191.11% |
| Profit Margin | -3191.11% |
| EBITDA Margin | -2671.23% |
| EBIT Margin | -2902.72% |
| FCF Margin | -2164.1% |
